MedTrace Logo

Severe Hypertriglyceridemia

Disease

Related News

Arrowhead Pharmaceuticals Reports Strong Long-Term Data for Plozasiran in Hypertriglyceridemia

Arrowhead Pharmaceuticals presented long-term data showing plozasiran achieved 83% median triglyceride reduction in severe hypertriglyceridemia patients with no acute pancreatitis events over two years. The RNA interference therapy demonstrated durable improvements in atherogenic lipoproteins and consistent safety profile. The company plans to complete Phase 3 studies by mid-2026 and submit for regulatory approval.

CRISPR Therapeutics Reports Wider-Than-Expected Q4 Loss, Sales Miss Estimates

CRISPR Therapeutics reported a Q4 2025 loss of $1.37 per share, missing estimates, with revenues of $0.9 million falling short of expectations. The company's partner Vertex recorded $54 million in Casgevy sales for the quarter, with regulatory submissions for pediatric label expansion planned for early 2026.

Related Clinical Trials

NCT ID Title Status Phase
NCT07604974

A Study to Assess the Safety, Tolerability and Efficacy of ION775

 RECRUITING PHASE2
NCT07269210

A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia

 RECRUITING PHASE2
NCT06880770

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

 RECRUITING PHASE3
NCT06555640

A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia

 COMPLETED PHASE2
NCT06347016

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

 ACTIVE_NOT_RECRUITING PHASE3
NCT06347003

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

 ACTIVE_NOT_RECRUITING PHASE3
NCT05852431

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

 ACTIVE_NOT_RECRUITING PHASE3
NCT05681351

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

 ACTIVE_NOT_RECRUITING PHASE3
NCT05552326

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

 COMPLETED PHASE3
NCT05355402

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

 COMPLETED PHASE2